Lifestyle Intervention for Weight Loss and Cardiometabolic Changes in the Setting of Glucokinase Regulatory Protein Inhibition | Zendy

L. Maria Belalcazar | Zendy; George D. Papandonatos | Zendy; Bahar Erar | Zendy; Inga Peter | Zendy; Hadeel Alkofide | Zendy; Ashok Balasubramanyam | Zendy; Ariel Brautbar | Zendy; Steven E. Kahn | Zendy; William C. Knowler | Zendy; Christie M. Ballantyne | Zendy; Jeanne M. McCaffery | Zendy; Gordon S. Huggins | Zendy

Open Access

Lifestyle Intervention for Weight Loss and Cardiometabolic Changes in the Setting of Glucokinase Regulatory Protein Inhibition

Author(s) -

L. Maria Belalcazar,

George D. Papandonatos,

Bahar Erar,

Inga Peter,

Hadeel Alkofide,

Ashok Balasubramanyam,

Ariel Brautbar,

Steven E. Kahn,

William C. Knowler,

Christie M. Ballantyne,

Jeanne M. McCaffery,

Gordon S. Huggins

Publication year - 2015

Publication title -

circulation cardiovascular genetics

Language(s) - English

Resource type - Journals

eISSN - 1942-325X

pISSN - 1942-3268

DOI - 10.1161/circgenetics.115.001192

Subject(s) - medicine , diabetes mellitus , overweight , triglyceride , weight loss , endocrinology , obesity , type 2 diabetes mellitus , cholesterol

Glucokinase regulatory protein (GCKR) inhibitors offer a novel treatment approach for glucose control in diabetes mellitus; however, their cardiometabolic effects, particularly in relation to increased triglycerides and C-reactive protein (CRP) levels, are of concern. GCKR Leu446Pro is a common variant associated with reduced GCKR function, increased triglycerides, and CRP.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research